John Oyler, BeiGene CEO (Endpoints News, PharmCube)
February 26, 2024 10:21 AM ESTUpdated March 2, 01:45 AM
Startups
Deals
Cell/Gene Tx

BeiGene ends pact with Shore­line, its 'en­try in­to cell ther­a­py'

Kyle LaHucik

Senior Reporter

BeiGene said its four-tar­get nat­ur­al killer cell ther­a­py col­lab­o­ra­tion with Shore­line Bio­sciences is over. And by reneg­ing on Shore­line’s iP­SC-NK cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times